The research interests of Lindsay A. Renfro, Ph.D., center on improving the efficiency and ethics of clinical trials and patient care in oncology. Dr. Renfro is particularly interested in Bayesian adaptive clinical trials, methodology for the evaluation and use of surrogate endpoints, biomarker-based trial design, and the construction and validation of clinical prediction models. Together, these areas lead to better integration of available data within and across clinical trials and improved tailoring of therapeutic research to patient subpopulations.
- Development and validation of prognostic models in oncology, including stage III colon cancer
- Improved methods for classical and Bayesian meta-analytic evaluation of candidate surrogate endpoints
- Bayesian adaptive trial designs for clinical trials utilizing surrogate endpoints
- Adaptive trial designs incorporating both identification and validation of continuous predictive biomarkers
Significance to patient care
The ultimate goal of Dr. Renfro's research is more efficient and ethical treatment of patients enrolled in cancer clinical trials, specifically through better trial design and better selection of endpoints used in clinical trials. Creation of more efficient and tailored clinical trials will also make promising therapies available sooner to nontrial cancer patients, and will identify therapies better tailored to specific subpopulations of patients with a given cancer. In addition, improved and rigorously validated prediction models (such as the tool Dr. Renfro created for stage III colon cancer) will enhance conversations between patients and physicians regarding prognoses and treatment decisions.
- President-Elect, Twin Cities Chapter of the American Statistical Association, 2016
- KL2 Mentored Career Development Program Scholar, 2015-2018
- Lead statistician, Experimental Therapeutics Committee, Alliance for Clinical Trials in Oncology, 2012-present
- Student paper award, Eastern North American Region, International Biometric Society, 2011